GlucoTrack, Inc. announced it is expanding its product pipeline with the commencement of a new R&D program for a long- term continuous glucose monitor. Following the recent acquisition of certain related IP, the Company intends to develop a long-term implantable glucose management technology to address the growing Type 1 diabetes market. Based on initial data, the Company believes it can bring to market a solution that is more accurate, more convenient and has a significantly longer duration than current on-the-market solutions.

In addition, as reported earlier this year, the Company completed lab testing of its non-invasive GlucoTrack 2.0 clinical prototype system and observed better-than-expected accuracy and performance with the technology. The Company is scheduled to begin its first-in-human trials later this quarter.